Loading company
AtriCure, Inc.
ATRC · Nasdaq · ·
Next earnings: November 4, 2026
$58.04-0.6%Sep 29 close
- 1M
- +18.6%
- 6M
- +105.0%
- 1Y
- +69.6%
- 5Y
- -20.0%
ATRC · Nasdaq · ·
Next earnings: November 4, 2026
$58.04-0.6%Sep 29 close
AtriCure, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $153.6M | $136.1M | +12.83% |
| Profit | $9M | -$6.2M | +244.67% |
| Profit per share | $0.18 | -$0.13 | +238.46% |
| Free Cash Flow | $18.4M | $19M | -2.79% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our team delivered healthy growth and a significant step up in profitability in the second quarter,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator ® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE ® and cryoXT ® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from AtriCure, Inc.’s Item 2.02 8-K filed July 23, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
AtriCure, Inc. has no earnings call transcript available.